DYN
Dyne Therapeutics, Inc.
$15.72
+0.10
(+0.64%)
Mkt Cap
2.94B
Volume
1,741,932
52W Range
14-27.31
Sector
Healthcare
Beta
1.12
EPS (TTM)
-3.33 USD
P/E Ratio
-5.64
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 506.00M | 1.37B | 842.00M | 1.47B |
| Net Income | (446.21M) | (317.42M) | (235.94M) | (168.10M) | (149.29M) | (58.74M) | (13.54M) | (4.81M) | 76.00M | (1.24B) | 50.00M | (67.00M) |
| EPS | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | -1.24 | -0.30 | -0.47 | 0.47 | -9.61 | 0.40 | -0.53 |
| Free Cash Flow | (405.13M) | (294.75M) | (188.89M) | (156.71M) | (123.18M) | (47.67M) | (13.48M) | (4.30M) | 361.00M | 350.00M | (181.00M) | (62.00M) |
| FCF / Share | -3.15 | -3.13 | -3.16 | -3.02 | -2.42 | -1.01 | -0.30 | -0.42 | 2.23 | 2.71 | -1.45 | -0.49 |
| Operating CF | (403.21M) | (292.37M) | (188.16M) | (153.65M) | (119.56M) | (46.51M) | (11.83M) | (4.16M) | 585.00M | 676.00M | 94.00M | (62.00M) |
| Total Assets | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M | 353.33M | 16.44M | 8.27M | 11.77B | 13.05B | 11.54B | 11.23B |
| Total Debt | 20.28M | 23.99M | 27.41M | 30.48M | 32.64M | 0 | 0 | 3.38M | 8.43B | 8.98B | 7.29B | 7.11B |
| Cash & Equiv | 893.37M | 435.45M | 121.63M | 172.15M | 200.82M | 300.85M | 14.63M | 8.12M | 365.00M | 1.78B | 505.00M | 1.87B |
| Book Value | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M | 342.37M | 14.04M | (4.88M) | 1.90B | 2.04B | 2.92B | 3.02B |
| Return on Equity | -0.46 | -0.50 | -2.58 | -0.67 | -0.41 | -0.17 | -0.96 | N/A | 0.04 | -0.61 | 0.02 | -0.02 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (178.56M) | (120.85M) | (111.95M) | (108.04M) | (110.86M) | (115.36M) | (89.54M) | (97.12M) | (65.10M) | (65.65M) | (66.64M) | (60.21M) |
| EPS | -1.08 | -0.73 | -0.76 | -0.76 | -0.97 | -1.05 | -0.88 | -0.96 | -0.70 | -0.81 | -1.09 | -0.99 |
| Free Cash Flow | (131.80M) | (145.14M) | (112.32M) | (109.96M) | (94.76M) | (106.87M) | (85.41M) | (74.88M) | (55.73M) | (78.73M) | (35.09M) | (50.77M) |
| FCF / Share | -0.80 | -0.88 | -0.87 | -0.78 | -0.83 | -0.97 | -0.84 | -0.74 | -0.60 | -0.97 | -0.57 | -0.83 |
| Operating CF | (130.29M) | (144.92M) | (111.83M) | (90.78M) | (94.70M) | (105.89M) | (84.33M) | (74.63M) | (54.87M) | (78.54M) | (35.01M) | (50.60M) |
| Total Assets | 994.01M | 1.08B | 1.19B | 867.06M | 728.99M | 721.07M | 691.23M | 768.84M | 825.88M | 522.28M | 165.08M | 205.24M |
| Total Debt | 19.87M | 19.30M | 20.28M | 120.47M | 121.08M | 23.33M | 23.99M | 24.86M | 25.72M | 26.62M | 27.41M | 28.23M |
| Cash & Equiv | 676.11M | 753.10M | 893.37M | 573.61M | 485.04M | 472.25M | 435.45M | 532.16M | 608.20M | 272.04M | 121.63M | 130.28M |
| Book Value | 702.15M | 865.05M | 972.13M | 691.78M | 571.45M | 668.97M | 629.84M | 705.54M | 775.19M | 478.06M | 91.29M | 152.04M |
| Return on Equity | -0.25 | -0.14 | -0.12 | -0.16 | -0.19 | -0.17 | -0.14 | -0.14 | -0.08 | -0.14 | -0.73 | -0.40 |
DYN News
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Stock Traders Buy High Volume of Dyne Therapeutics Call Options (NASDAQ:DYN)
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Dyne Therapeutics, Inc. $DYN is Atlas Venture Life Science Advisors LLC’s 2nd Largest Position
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting